Drug Profile
NBI 921352
Alternative Names: NBI-921352; XEN 901Latest Information Update: 25 Apr 2024
Price :
$50
*
At a glance
- Originator Xenon Pharmaceuticals
- Developer Neurocrine Biosciences; Xenon Pharmaceuticals
- Class Antiepileptic drugs; Small molecules
- Mechanism of Action Nav1.6 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Epilepsy
- Discontinued Dravet syndrome; Seizures
Most Recent Events
- 12 Apr 2024 Neurocrine Biosciences terminated a phase II long-term extension trial for Seizures (Adjunctive treatment) in Hungary, Australia, Belgium, Czech Republic, France, Italy, and Spain (PO) bcz parent study failed to meet its primary endpoint (NCT05493293)
- 31 Dec 2023 Xenon Pharmaceuticals has patent protection for NBI 921352 Worldwide
- 31 Dec 2023 Xenon Pharmaceuticals has patent protection for NBI 921352 in US